CAR-T immunotherapy provides customized treatment for a patient’s cancer. The therapy involves modifying a patient’s immune system T-cells to hunt and direct an attack against cancer cells. Through clinical trials, UNC Lineberger researchers are offering patients innovative treatments for cancers that have not responded to other treatments.
These stories offer insight about CAR-T therapy as an option for patients, and the possibilities it brings to cancer care.
CAR-T therapy gives patient options after cancer returns
When traditional cancer treatment options failed, Sabrina Shelton’s care team referred her to UNC for a CAR-T therapy clinical trial.
Patient and care team fight relapsed cancer with immunotherapy
When his lymphoma recurred just 18 months after treatment, Jeff Nichols enrolled in a CAR-T clinical trial at UNC Lineberger.
Road trip for CAR-T offers hope for patient after cancer relapse
Donielle DuBois traveled to Chapel Hill to receive CAR-T immunotherapy for her Hodgkin lymphoma, which had recurred after being in remission for several years.
A cancer journey provides a new career path
After two cancer diagnoses and multiple rounds of treatment, Lauren Gift’s cancer journey inspired her to help others navigate cancer treatment.